Table 4.
Change in effectiveness outcomes after 24 weeks of treatment with biphasic insulin aspart 30 by age-group
| Measurement [mean (SD)] | ≤40 years | >40–65 years | >65 years | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change after 24 weeks | p valuea | Baseline | Change after 24 weeks | p valuea | Baseline | Change after 24 weeks | p valuea | |
| HbA1c | |||||||||
| Entire cohort (%) | 9.6 (1.8) | −2.3 (1.8) | <0.001 | 9.5 (1.7) | −2.0 (1.6) | <0.001 | 9.4 (1.8) | −2.0 (1.8) | <0.001 |
| Entire cohort (mmol/mol) | 81.4 (19.7) | −25.1 (19.7) | <0.001 | 80.3 (18.6) | −23.0 (17.5) | <0.001 | 79.2 (19.7) | −21.9 (19.7) | <0.001 |
| n | 2,908 | 19,681 | 4,052 | ||||||
| Insulin-experienced (%) | 9.5 (1.9) | −2.0 (1.9) | <0.001 | 9.4 (1.7) | −1.8 (1.7) | <0.001 | 9.3 (1.8) | −1.8 (1.8) | <0.001 |
| Insulin-experienced(mmol/mol) | 80.3 (20.8) | −26.2 (20.8) | <0.001 | 79.2 (18.6) | −23.0 (18.6) | <0.001 | 78.1 (19.7) | −24.0 (19.7) | <0.001 |
| n | 676 | 5,983 | 1,809 | ||||||
| Insulin-naïve (%) | 9.6 (1.8) | −2.4 (1.8) | <0.001 | 9.5 (1.6) | −2.1 (1.6) | <0.001 | 9.5 (1.9) | −2.2 (1.8) | <0.001 |
| Insulin-naïve (mmol/mol) | 81.4 (19.7) | −21.9 (19.7) | <0.001 | 80.3 (17.5) | −19.7 (17.5) | <0.001 | 80.3 (20.8) | −19.7 (19.7) | <0.001 |
| n | 2,232 | 13,698 | 2,243 | ||||||
| FPG before breakfast (mmol/l) | |||||||||
| Entire cohort | 11.1 (3.7) | −4.2 (3.6) | <0.001 | 11.0 (3.5) | −3.8 (3.4) | <0.001 | 10.5 (3.7) | −3.4 (3.8) | <0.001 |
| n | 3,111 | 21,647 | 4,736 | ||||||
| Insulin-experienced | 10.9 (3.9) | −3.7 (4.2) | <0.001 | 10.7 (3.7) | −3.4 (3.8) | <0.001 | 10.2 (3.9) | −3.0 (4.0) | <0.001 |
| n | 685 | 6,367 | 2,046 | ||||||
| Insulin-naïve | 11.2 (3.6) | −4.3 (3.3) | <0.001 | 11.1 (3.3) | −4.0 (3.2) | <0.001 | 10.7 (3.5) | −3.7 (3.6) | <0.001 |
| n | 2,426 | 15,280 | 2,690 | ||||||
| PPG after breakfast (mmol/l) | |||||||||
| Entire cohort | 15.7 (4.5) | −6.1 (4.6) | <0.001 | 15.3 (4.2) | −5.4 (4.3) | <0.001 | 14.7 (4.6) | −4.8 (4.9) | <0.001 |
| n | 2,070 | 15,317 | 3,230 | ||||||
| Insulin-experienced | 14.4 (4.7) | −4.7 (4.9) | <0.001 | 14.4 (4.4) | −4.6 (4.4) | <0.001 | 13.9 (4.7) | −4.1 (4.8) | <0.001 |
| n | 463 | 4,287 | 1,361 | ||||||
| Insulin-naïve | 16.1 (4.4) | −6.5 (4.4) | <0.001 | 15.6 (4.1) | −5.8 (4.3) | <0.001 | 15.3 (4.5) | −5.2 (4.9) | <0.001 |
| n | 1,607 | 11,030 | 1,869 | ||||||
| HRQoL (VAS) | |||||||||
| Entire cohort | 62.8 (17.5) | 17.1 (18.6) | <0.001 | 63.7 (16.8) | 13.7 (16.6) | <0.001 | 63.3 (16.6) | 12.3 (16.9) | <0.001 |
| n | 2,787 | 19,304 | 4,677 | ||||||
| Insulin-experienced | 67.6 (17.0) | 11.8 (17.3) | <0.001 | 66.0 (16.2) | 10.6 (16.0) | <0.001 | 62.6 (16.6) | 11.2 (17.2) | <0.001 |
| n | 550 | 5,381 | 1,925 | ||||||
| Insulin-naïve | 61.6 (17.4) | 18.5 (18.6) | <0.001 | 62.8 (16.9) | 14.9 (16.7) | <0.001 | 63.7 (16.6) | 13.1 (16.6) | <0.001 |
| n | 2,237 | 13,923 | 2,752 | ||||||
Due to the non-interventional nature of this study, not all baseline data were recorded and some patients were lost to follow-up
FPG fasting plasma glucose, HbA 1c glycated hemoglobin, HRQoL health-related quality of life, PPG post-prandial plasma glucose, VAS visual analog scale
a p values vs. baseline